AYOXXA appoints permanent CEO
Cologne, December 7, 2017
The Supervisory Board of AYOXXA Biosystems GmbH is pleased to announce that following his initial assumption of the duties of CEO in October 2016, Rodney Turner will continue to lead the company as CEO on a permanent basis effective immediately. The board and Mr. Turner are aligned on the future growth opportunities for AYOXXA which focus on bringing it’s state-of-the-art LUNARIS™ multiplex immunoassay system to users for the first time, and expanding partnerships in the development and use of the platform. Mr. Turner has served as an independent board member of AYOXXA since July 2014. He was a senior corporate development executive at Life Technologies from 2006 to 2014 and prior to that period, had a notable career as a senior business development executive at a number of biotech start-ups, including EVOTEC AG and Fluidigm Corporation.
“I am very pleased to further formalize my leadership role at AYOXXA and glad to be based in Cologne so that I can participate directly with the AYOXXA team as we focus on using the LUNARIS™ platform to advance the research objectives of our customers,” said Mr. Turner.
“The Supervisory Board is glad to secure the services of Mr. Turner on a long-term basis to lead AYOXXA and fully supports the growth of the business and expansion of the team at AYOXXA as the company enters this exciting phase of growth,” commented Dr. Gerald Möller, Chairman of the AYOXXA Supervisory Board.
AYOXXA Biosystems GmbH
Dr. Marion Lammertz
Marketing Manager Communications
Phone: +49 (0) 221 222529 41
AYOXXA Biosystems GmbH is an international biotech company based in Cologne (Germany) with offices in Boston (USA) and Singapore. LUNARIS™ is AYOXXA’s innovative, patented beads-on-a-chip technology platform to analyze picogram amounts of multiple biomarkers in biological samples.
It delivers a high-quality immune-assay for sample volumes down to single-digit microliter, greatly expanding the types and number of samples from which scientists can gain insights. AYOXXA opens protein multiplexing opportunities to biomedicine, all the way from basic research to clinic and translational discoveries covering ophthalmology, mouse-to-man and immuno-oncology applications.
AYOXXA commercializes a portfolio of ready-to-use biomarker detection kits, e.g. LUNARIS™ Human & Mouse 5 to 12-Plex Cytokine Kits. With the introduction of AYOXXA Reader AR01, the company now offers a fully integrated solution for LUNARIS™ multiprotein analysis.